JP2010521476A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010521476A5 JP2010521476A5 JP2009553689A JP2009553689A JP2010521476A5 JP 2010521476 A5 JP2010521476 A5 JP 2010521476A5 JP 2009553689 A JP2009553689 A JP 2009553689A JP 2009553689 A JP2009553689 A JP 2009553689A JP 2010521476 A5 JP2010521476 A5 JP 2010521476A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hcv
- hydrogen
- inhibitor
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 41
- 229910052739 hydrogen Inorganic materials 0.000 claims 26
- 239000001257 hydrogen Substances 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000000753 cycloalkyl group Chemical group 0.000 claims 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 17
- 239000003112 inhibitor Substances 0.000 claims 12
- -1 hydroxy, benzyloxy Chemical group 0.000 claims 11
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 229940121649 protein inhibitor Drugs 0.000 claims 8
- 239000012268 protein inhibitor Substances 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 125000001188 haloalkyl group Chemical group 0.000 claims 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000002393 azetidinyl group Chemical group 0.000 claims 4
- 125000002757 morpholinyl group Chemical group 0.000 claims 4
- 125000004193 piperazinyl group Chemical group 0.000 claims 4
- 125000003386 piperidinyl group Chemical group 0.000 claims 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 4
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 3
- 108010036949 Cyclosporine Proteins 0.000 claims 3
- 229940122750 HCV entry inhibitor Drugs 0.000 claims 3
- 102000014150 Interferons Human genes 0.000 claims 3
- 108010050904 Interferons Proteins 0.000 claims 3
- 102000015696 Interleukins Human genes 0.000 claims 3
- 108010063738 Interleukins Proteins 0.000 claims 3
- 101800001019 Non-structural protein 4B Proteins 0.000 claims 3
- 101800001014 Non-structural protein 5A Proteins 0.000 claims 3
- 229940122055 Serine protease inhibitor Drugs 0.000 claims 3
- 101710102218 Serine protease inhibitor Proteins 0.000 claims 3
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 3
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229960001265 ciclosporin Drugs 0.000 claims 3
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims 3
- 229930182912 cyclosporin Natural products 0.000 claims 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims 3
- 125000004692 haloalkylcarbonyl group Chemical group 0.000 claims 3
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 claims 3
- 229940079322 interferon Drugs 0.000 claims 3
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 239000003001 serine protease inhibitor Substances 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 229940124683 HCV polymerase inhibitor Drugs 0.000 claims 2
- 229940121759 Helicase inhibitor Drugs 0.000 claims 2
- 208000005176 Hepatitis C Diseases 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 108060004795 Methyltransferase Proteins 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89488707P | 2007-03-14 | 2007-03-14 | |
| US60/894,887 | 2007-03-14 | ||
| US98947407P | 2007-11-21 | 2007-11-21 | |
| US60/989,474 | 2007-11-21 | ||
| PCT/US2008/055893 WO2008112473A1 (en) | 2007-03-14 | 2008-03-05 | Compounds for the treatment of hepatitis c |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010521476A JP2010521476A (ja) | 2010-06-24 |
| JP2010521476A5 true JP2010521476A5 (show.php) | 2011-04-14 |
| JP5232178B2 JP5232178B2 (ja) | 2013-07-10 |
Family
ID=39477552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009553689A Expired - Fee Related JP5232178B2 (ja) | 2007-03-14 | 2008-03-05 | Ｃ型肝炎の治療のための化合物 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7547690B2 (show.php) |
| EP (1) | EP2118109B1 (show.php) |
| JP (1) | JP5232178B2 (show.php) |
| KR (1) | KR20100015304A (show.php) |
| CN (1) | CN101657455B (show.php) |
| AR (1) | AR065772A1 (show.php) |
| AU (1) | AU2008226639B2 (show.php) |
| BR (1) | BRPI0808763A2 (show.php) |
| CA (1) | CA2681093A1 (show.php) |
| CL (1) | CL2008000751A1 (show.php) |
| CO (1) | CO6180426A2 (show.php) |
| EA (1) | EA016614B1 (show.php) |
| IL (1) | IL200905A0 (show.php) |
| MX (1) | MX2009009473A (show.php) |
| NZ (1) | NZ579342A (show.php) |
| PE (1) | PE20090648A1 (show.php) |
| TW (1) | TW200848058A (show.php) |
| WO (1) | WO2008112473A1 (show.php) |
| ZA (1) | ZA200906129B (show.php) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1688420A4 (en) * | 2003-11-19 | 2008-10-22 | Japan Tobacco Inc | 5-5 LOW-CONDENSED HETEROCYCLIC COMPOUND AND THEIR USE AS HCV POLYMERASE INHIBITOR |
| US20070049593A1 (en) | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
| US7521443B2 (en) * | 2006-05-17 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US8143243B2 (en) * | 2007-08-09 | 2012-03-27 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7642251B2 (en) * | 2007-08-09 | 2010-01-05 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7652004B2 (en) * | 2007-08-09 | 2010-01-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| CN101918410B (zh) * | 2007-11-20 | 2013-02-27 | 百时美施贵宝公司 | 与环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂 |
| US8124601B2 (en) | 2007-11-21 | 2012-02-28 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US8129367B2 (en) * | 2007-11-21 | 2012-03-06 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| BRPI0821836A2 (pt) | 2007-12-24 | 2015-06-16 | Tibotec Pharm Ltd | Indóis macrocíclicos como inibidores do vírus da hepatite c |
| MX2010010061A (es) * | 2008-03-27 | 2010-09-30 | Bristol Myers Squibb Co | Compuestos para el tratamiento de hepatitis c. |
| JP2011515496A (ja) * | 2008-03-27 | 2011-05-19 | ブリストル−マイヤーズ スクイブ カンパニー | ジオキソランおよびジオキソラノン縮合インドロベンザジアゼピンｈｃｖｎｓ５ｂ阻害剤 |
| MX2010010235A (es) * | 2008-03-27 | 2010-10-05 | Bristol Myers Squibb Co | Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados a pirrolidina. |
| US8133884B2 (en) * | 2008-05-06 | 2012-03-13 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8143244B2 (en) * | 2009-02-26 | 2012-03-27 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| PE20121556A1 (es) * | 2009-12-07 | 2012-12-05 | Targacept Inc | 3,6-diazabiciclo[3.1.1]heptanos como ligandos de receptores nicotinicos neuronales de acetilcolina |
| US8716275B2 (en) * | 2011-10-20 | 2014-05-06 | Bristol-Myers Squibb Company | Compound for the treatment of hepatitis C |
| WO2014011863A1 (en) * | 2012-07-12 | 2014-01-16 | Targacept, Inc. | Method of treatment with 3-cyclopropylcarbonyl-3,6-diazabicyclo[3.1.1]heptane |
| AU2013290402A1 (en) * | 2012-07-18 | 2015-03-05 | Bristol-Myers Squibb Holdings Ireland | Novel methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3-methoxy-5a-((1 r,5s) -3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide |
| BR112018068638A2 (pt) | 2016-03-15 | 2019-02-05 | Bayer Cropscience Ag | sulfonamidas substituídas para controle de pragas animais |
| TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
| CN110028510A (zh) * | 2019-05-22 | 2019-07-19 | 南京合巨药业有限公司 | 一种3-甲基-3,6-二氮杂-双环[3,1,1]庚烷二盐酸盐的制备方法 |
| EP4055010A1 (de) | 2019-11-07 | 2022-09-14 | Bayer Aktiengesellschaft | Substituierte sulfonylamide zur bekämpfung tierischer schädlinge |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1719773T3 (pl) | 2004-02-24 | 2009-08-31 | Japan Tobacco Inc | Skondensowane związki heterotetracykliczne i ich zastosowanie jako inhibitora polimerazy HCV |
| US7348425B2 (en) | 2004-08-09 | 2008-03-25 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| US7662809B2 (en) | 2004-10-26 | 2010-02-16 | Istituto Di Richerche Di Biologia Molecolare P Angeletti Spa | Tetracyclic indole derivatives as antiviral agents |
| GB0518390D0 (en) | 2005-09-09 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US7399758B2 (en) | 2005-09-12 | 2008-07-15 | Meanwell Nicholas A | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7473688B2 (en) | 2005-09-13 | 2009-01-06 | Bristol-Myers Squibb Company | Indolobenzazepine HCV NS5B inhibitors |
| US7456165B2 (en) | 2006-02-08 | 2008-11-25 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
| GB0608928D0 (en) | 2006-05-08 | 2006-06-14 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| US7456166B2 (en) * | 2006-05-17 | 2008-11-25 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7521441B2 (en) | 2006-05-22 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| ES2343914T3 (es) | 2006-05-25 | 2010-08-12 | Bristol-Myers Squibb Company | Inhibidores de ns5b de hcv de indolobenzazepina condensada con ciclopropilo. |
| US7521442B2 (en) | 2006-05-25 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7452876B2 (en) | 2006-06-08 | 2008-11-18 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
-
2008
- 2008-02-28 US US12/039,239 patent/US7547690B2/en active Active
- 2008-03-05 CN CN200880008369XA patent/CN101657455B/zh not_active Expired - Fee Related
- 2008-03-05 CA CA002681093A patent/CA2681093A1/en not_active Abandoned
- 2008-03-05 KR KR1020097019018A patent/KR20100015304A/ko not_active Ceased
- 2008-03-05 EA EA200901241A patent/EA016614B1/ru not_active IP Right Cessation
- 2008-03-05 AU AU2008226639A patent/AU2008226639B2/en not_active Ceased
- 2008-03-05 WO PCT/US2008/055893 patent/WO2008112473A1/en not_active Ceased
- 2008-03-05 EP EP08743684.6A patent/EP2118109B1/en not_active Not-in-force
- 2008-03-05 JP JP2009553689A patent/JP5232178B2/ja not_active Expired - Fee Related
- 2008-03-05 MX MX2009009473A patent/MX2009009473A/es not_active Application Discontinuation
- 2008-03-05 BR BRPI0808763-6A patent/BRPI0808763A2/pt not_active IP Right Cessation
- 2008-03-05 NZ NZ579342A patent/NZ579342A/en not_active IP Right Cessation
- 2008-03-13 PE PE2008000473A patent/PE20090648A1/es not_active Application Discontinuation
- 2008-03-13 CL CL200800751A patent/CL2008000751A1/es unknown
- 2008-03-13 TW TW097108906A patent/TW200848058A/zh unknown
- 2008-03-14 AR ARP080101085A patent/AR065772A1/es not_active Application Discontinuation
-
2009
- 2009-09-03 ZA ZA2009/06129A patent/ZA200906129B/en unknown
- 2009-09-10 CO CO09097263A patent/CO6180426A2/es active IP Right Grant
- 2009-09-13 IL IL200905A patent/IL200905A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010521476A5 (show.php) | ||
| JP2010515752A5 (show.php) | ||
| JP2010521481A5 (show.php) | ||
| JP2010521484A5 (show.php) | ||
| JP2010521483A5 (show.php) | ||
| HRP20110194T1 (hr) | Ciklopropil fuzionirani indolobenzazepini kao inhibitori hcv ns5b | |
| US8426458B2 (en) | Hepatitis C Virus inhibitors | |
| US8420686B2 (en) | Linked diimidazole antivirals | |
| US8703938B2 (en) | Hepatitis C virus inhibitors | |
| JP2012504632A5 (show.php) | ||
| JP2010510234A5 (show.php) | ||
| US9060971B2 (en) | Combination pharmaceutical agents as inhibitors of HCV replication | |
| US8314135B2 (en) | Linked dibenzimidazole antivirals | |
| JP2012512169A5 (show.php) | ||
| JP2012504132A5 (show.php) | ||
| JP2011523651A5 (show.php) | ||
| JP2008530096A5 (show.php) | ||
| JP2011521965A5 (show.php) | ||
| JP2012528161A5 (show.php) | ||
| MY146123A (en) | Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatment using the same | |
| AR065772A1 (es) | Compuestos de indolobenzazepina para el tratamiento de la hepatitis c. composiciones farmaceuticas. | |
| JP2012504126A5 (show.php) | ||
| JP2012511004A5 (show.php) | ||
| JP2010508362A5 (show.php) | ||
| WO2004014313A3 (en) | Combination pharmaceutical agents as inhibitors of hcv replication |